Functional assessment of CYP3A4 and CYP2C19 genetic polymorphisms on the metabolism of clothianidin in vitro

被引:0
作者
Hu, Yingying [1 ]
Ye, Zhize [2 ]
Wu, Hualu [1 ]
Chen, Xiaohai [1 ]
Xia, Hailun [1 ]
Cai, Jian-ping [3 ]
Hu, Guo-xin [4 ]
Xu, Ren-ai [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China
[2] Shaoxing Peoples Hosp, Shaoxing, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci, Inst Geriatr Med, Key Lab Geriatr,Beijing Inst Geriatr, Beijing Hosp,Natl Ctr Gerontol,Natl Hlth Commiss, Beijing, Peoples R China
[4] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China
关键词
Clothianidin; Variants; Metabolism; ALLELIC VARIANTS; RAPID METABOLIZER; IDENTIFICATION; GENOTYPE; EXPOSURE; ENZYMES; RISK;
D O I
10.1016/j.cbi.2024.111154
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clothianidin, classified as a second-generation neonicotinoid, has achieved extensive application due to its high efficacy against insect pests. This broad-spectrum usage has resulted in its frequent detection in environmental surveys. CYP2C19 and CYP3A4 are crucial for converting clothianidin to desmethyl-clothianidin (dm-clothianidin). The expression of these CYP450s can be significantly influenced by genetic polymorphisms. The objective of our research was to examine the catalytic effects of 27 CYP3A4 variants and 31 CYP2C19 variants on the metabolism of clothianidin within recombinant insect microsomes. These variants were assessed through a wellestablished incubation procedure. In addition, the concentration of its metabolite dm-clothianidin was quantified by employing an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Lastly, the kinetic parameters of these CYP3A4 and CYP2C19 variants were calculated by applying Michaelis-Menten kinetic analysis to fit the data. The observed changes in enzyme activity were related to the metabolic transformation of clothianidin to dm-clothianidin. In the CYP2C19 metabolic pathway, one variant (CYP2C19.23) showed no notable change in intrinsic clearance (CLint), four variants (CYP2C19.29, .30, .31 and L16F) demonstrated a marked increase in CLint(110.86-183.46 %), and the remaining 25 variants exhibited a considerable decrease in CLint(26.38-89.79 %), with a maximum decrease of 73.62 % (CYP2C19.6). In the CYP3A4 metabolic pathway, 26 variants demonstrated significantly reduced CLint(10.54-52.52 %), with a maximum decrease of 89.46 % (CYP3A4.20). Our results suggested that most variants of CYP3A4 and CYP2C19 significantly altered the enzymatic activities associated with clothianidin metabolism to various degrees. This study provides new insights into assessing the metabolic behavior of pesticides and delivers crucial data that can guide clinical detoxification strategies.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates
    Florian Simon
    Elodie Gautier-Veyret
    Aurélie Truffot
    Marylore Chenel
    Léa Payen
    Françoise Stanke-Labesque
    Michel Tod
    Pharmaceutical Research, 2021, 38 : 415 - 428
  • [32] Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine
    Gruen, Barbara
    Merkel, Ulrike
    Riedel, Klaus-Dieter
    Weiss, Johanna
    Mikus, Gerd
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) : 854 - 863
  • [33] Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects
    Yoo, H-D
    Park, S-A
    Cho, H-Y
    Lee, Y-B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (03) : 281 - 284
  • [34] Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4
    Yoo, Sung-Eun
    Yi, MyeongJin
    Kim, Woo-Young
    Cho, Sun-Ah
    Lee, Sang Seop
    Lee, Su-Jun
    Shin, Jae-Gook
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (03) : 201 - 208
  • [35] The associations of genetic polymorphisms in CYP1A2 and CYP3A4 with clinical outcomes of breast cancer patients in northern China
    Bai, Xianan
    Xie, Jingjing
    Sun, Shanshan
    Zhang, Xianyu
    Jiang, Yongdong
    Pang, Da
    ONCOTARGET, 2017, 8 (24) : 38367 - 38377
  • [36] Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates
    Simon, Florian
    Gautier-Veyret, Elodie
    Truffot, Aurelie
    Chenel, Marylore
    Payen, Lea
    Stanke-Labesque, Francoise
    Tod, Michel
    PHARMACEUTICAL RESEARCH, 2021, 38 (03) : 415 - 428
  • [37] Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro
    Li, Ying-hui
    Lu, Xiang-ran
    Lin, Qian-meng
    Huang, Huan-le
    Liang, Xiao-long
    Cai, Jian-ping
    Cui, Ju
    Hu, Guo-xin
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2019, 71 (11) : 1677 - 1683
  • [38] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
    Allabi, AC
    Gala, JL
    Desager, JP
    Heusterspreute, M
    Horsmans, Y
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) : 653 - 657
  • [39] Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma
    Zhou, Weiwei
    An, Guangyu
    Jian, Yuan
    Guo, Huan
    Chen, Wenming
    ONCOLOGY LETTERS, 2015, 10 (02) : 1171 - 1175
  • [40] Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population
    Hu, Li-Ming
    Dai, Da-Peng
    Hu, Guo-Xin
    Yang, Jie-Fu
    Xu, Ren-Ai
    Yang, Li-Ping
    Qian, Jian-Chang
    Ge, Ren-Shan
    Cai, Jian-Ping
    PHARMACOGENOMICS, 2012, 13 (14) : 1571 - 1581